Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data

被引：0
|
作者：
Ashish Sharma
M. Hafeez Faridi
Nilesh Kumar
Nikulaa Parachuri
Rohini Sharma
Baruch D. Kuppermann
Francesco Bandello
Anat Loewenstein
Carl D. Regillo
机构：
[1] Lotus Eye Hospital and Institute,Department of Vitreoretina
[2] Chicago State University,College of Pharmacy
[3] The TIPS Global Institute,Department of Healthcare
[4] University of California,Gavin Herbert Eye Institute
[5] Scientific Institute San Raffaele,Department of Ophthalmology; University Vita
[6] Tel Aviv University,Salute
[7] Mid Atlantic Retina,Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine
来源：
Eye | 2020年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1008 / 1009
页数：1
相关论文
共 50 条
  • [31] LONG-TERM FOLLOW-UP OF STARTING AND SWITCHING FROM ORIGINAL ADALIMUMAB TO ADALIMUMAB BIOSIMILAR: REAL-WORLD DATA IN AXIAL SPONDYLOARTHRITIS
    Pinto, A. S.
    Flora, K.
    Matharu, D.
    Isaacs, A.
    Machado, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 780 - 780
  • [32] Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial) : Real-World Evidence
    Chakraborty, Debdulal
    Mondal, Soumen
    Boral, Subhendu
    Das, Arnab
    Sinha, Tushar Kanti
    Majumdar, Saptorshi
    Bhattacharya, Ranabir
    Maitra, Ritobroto
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 1067 - 1076
  • [33] Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar
    Kay, Jonathan
    Doerner, Thomas
    Emery, Paul
    Kvien, Tore K.
    Breedveld, Ferdinand C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (04) : E44 - +
  • [34] REAL-WORLD TREATMENT PATTERNS OF RANIBIZUMAB AMONG PATIENTS WITH RETINAL DISEASES IN CANADA: 5 YEARS OF DATA
    Rousseau, C.
    Saad, R.
    Davies, B.
    Zaour, N.
    VALUE IN HEALTH, 2015, 18 (07) : A428 - A428
  • [35] Real-World Results of Intravitreal Ranibizumab, Bevacizumab, or Triamcinolone for Diabetic Macular Edema
    Koc, Irem
    Kadayifcilar, Sibel
    Eldem, Bora
    OPHTHALMOLOGICA, 2018, 239 (2-3) : 85 - 93
  • [36] REAL-WORLD EXPERIENCE OF SWITCHING FROM ORIGINATOR TO BIOSIMILAR RITUXIMAB IN RHEUMATOID ARTHRITIS
    Melville, A.
    Yusof, M. Y. Md
    Fitton, J.
    Bailey, L.
    Emery, P.
    Buch, M. H.
    Dass, S.
    Saleem, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 299 - 300
  • [37] An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
    Eldem, Bora
    Lai, Timothy Y. Y.
    Ngah, Nor Fariza
    Vote, Brendan
    Yu, Hyeong Gon
    Fabre, Alban
    Backer, Arthur
    Clunas, Nathan J.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2018, 256 (05) : 963 - 973
  • [38] An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
    Bora Eldem
    Timothy Y. Y. Lai
    Nor Fariza Ngah
    Brendan Vote
    Hyeong Gon Yu
    Alban Fabre
    Arthur Backer
    Nathan J. Clunas
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256 : 963 - 973
  • [39] Real-World Treatment Patterns and Vision Outcomes with Ranibizumab for Diabetic Macular Edema
    Naujokaitis, Tadas
    Balciuniene, Vilma Jurate
    JOURNAL OF OPHTHALMOLOGY, 2021, 2021
  • [40] Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
    Popescu, Claudiu Costinel
    Mogosan, Corina Delia
    Enache, Luminita
    Codreanu, Catalin
    MEDICINA-LITHUANIA, 2022, 58 (12):
12345